For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...
EGFR-positive lung cancer is a type of lung cancer with an epidermal growth factor receptor (EGFR) mutation. In the United States, around 10% to 15% of lung cancers are EGFR-positive. Most of these ...
Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...
Lung cancer is the top cause of cancer-related deaths globally, more prevalent in men, and ranks third among women. Both ...
Comprehensive biomarker testing can identify EGFR or other mutations in your lung cancer. Learn the benefits of testing and how it can help shape treatment.
In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable ...
A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...
EGFR, epidermal growth factor receptor, is a protein found on the surface of your cells that makes them grow. If you have non-small-cell lung cancer (NSCLC), your cancer might carry certain ...
Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.
After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for ...
Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR is involved in several cancer developments, including NSCLC. The EGFR pathway regulates the Bax/Bcl-2 cascade in ...
Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...